Merus focuses on the discovery and development of OligoclonicsTM and Bispecific antibody product candidates against targets in oncology, chronic inflammation and infectious diseases.
OligoclonicsTM are selected for synergistic effects in in vitro assays and in vivo models of human disease. After production of mixtures in a single, clonal cell, superiority over single monoclonal antibody therapies is established.
Current targets include combinations of surface expressed molecules on tumor cells, cytokines and viruses. Merus plans to take one or more of the most promising product candidates into clinical development to establish the regulatory acceptance and manufacturing applicability of OligoclonicsTM and Bispecifics and to provide proof of superior clinical efficacy.